Market Overview

As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy


The Vetr crowd on Thursday upgraded its rating for GlaxoSmithKline plc (ADR) (NYSE: GSK) from 3 stars (Hold), issued 527 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Share price in GSK took a pronounced downturn throughout April, in part due to the company's recall of 600,000 defective inhalers that occasionally failed in delivering the correct amount of medication per use.

GSK's stock has fallen more than 2.5 percent since the beginning of the month and was recently trading around $40.80.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for GlaxoSmithKline is up at $45.30, which is still just below the average analyst target price of $45.67. Less than 2 percent of Vetr users are holding GSK in their watch lists.

Latest Ratings for GSK

Nov 2019UBSUpgradesNeutralBuy
Nov 2019Argus ResearchMaintainsBuy
Oct 2019New StreetUpgradesReduceHold

View More Analyst Ratings for GSK
View the Latest Analyst Ratings


Related Articles (GSK)

View Comments and Join the Discussion!

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings General

Latest Ratings

PDCEImperial CapitalMaintains18.0
MSGEImperial CapitalInitiates Coverage On73.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at